Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

V.H.J. van der Velden, A. Sluijs-Geling, B.E.S. Gibson, J.G.T. Marvelde, P.G. Hoogeveen, W.C.J. Hop, K. Wheatley, M.B. Bierings, G.J. Schuurhuis, S.S.N. de Graaf, E.R. van Wering, J.J.M. van Dongen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1599-1606
JournalLeukemia
Volume24
Issue number9
DOIs
Publication statusPublished - 2010

Cite this

van der Velden, V. H. J., Sluijs-Geling, A., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., ... van Dongen, J. J. M. (2010). Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24(9), 1599-1606. https://doi.org/10.1038/leu.2010.153